The case for a temporary waiver on IP for Covid-19 vaccines

The West has hoarded vaccines and blocked developing nations from making their own, citing intellectual property protections. WTO and President Biden can put a stop to that.

Employees at a Pfizer vaccine plant in Belgium last month. A temporary suspension of intellectual property provisions, which prevent developing nations' access to the technology needed to make their own versions of Western-made Covid-19 vaccines, wou
Employees at a Pfizer vaccine plant in Belgium last month. A temporary suspension of intellectual property provisions, which prevent developing nations' access to the technology needed to make their own versions of Western-made Covid-19 vaccines, would hardly hit drug firms' bottom lines, says the writer. PHOTO: REUTERS

I've had my first Covid-19 vaccine jab, drawn from the limited supply of the AstraZeneca doses that has made its way to the developing world. As a senior, I'm part of a so-called priority sector eligible to receive it in the Philippines, a country where less than 0.3 per cent of the population has been fully vaccinated - versus 32 per cent in the United States. I'm one of the lucky ones.

Globally, more than 1.16 billion doses of Covid-19 vaccine have been administered as of Monday. Over 80 per cent have gone to people in high-or upper-middle-income countries and only 0.2 per cent to those in low-income countries like the Philippines. At present, India is suffering from a devastating surge of the virus, with over 350,000 infections and 3,000 deaths recorded daily over the past few days. (These figures most likely undercount the full extent of the horror.) Only 2 per cent of its people have been fully vaccinated. While US President Joe Biden's recent deployment of aid to India is commendable, fresh supplies and 60 million potentially spoilt doses of the AstraZeneca vaccine will not solve the problem.

Already a subscriber? 

Read the full story and more at $9.90/month

Get exclusive reports and insights with more than 500 subscriber-only articles every month

Unlock these benefits

  • All subscriber-only content on ST app and straitstimes.com

  • Easy access any time via ST app on 1 mobile device

  • E-paper with 2-week archive so you won't miss out on content that matters to you

Join ST's Telegram channel and get the latest breaking news delivered to you.

A version of this article appeared in the print edition of The Straits Times on May 05, 2021, with the headline The case for a temporary waiver on IP for Covid-19 vaccines. Subscribe